NewsBenzingaVor Bio anuncia que los datos del ensayo de fase 3 de telitacicept por parte de su socio RemeGen demuestran que más del 95% de los participantes lograron una mejora de al menos 5 puntos en MG-ADL durante 48 semanas Vor Bio anuncia que los datos del ensayo de fase 3 de telitacicept por parte de su socio RemeGen demuestran que más del 95% de los participantes lograron una mejora de al menos 5 puntos en MG-ADL durante 48 semanas Benzinga 2026.09.29 12:07 (GMT+0) Open on Benzinga Other news OpenAI’s September Annualized Revenue $20B Below Earlier Estimates, AI Stocks Fall - TipRanks.com Why Is Hut 8 Stock Trending After Hours? Starknet considers transitioning to an L1 network to counter quantum threats, targeting 2027 Securitize Stock Jumps After Hours As It Launches Tokenized Apple, Nvidia, Tesla Shares On Solana How to Play AMD Stock as It Continues to Explore a Foundry Partnership With a Korean Tech Giant Trump Says Calling It ‘Artificial Intelligence’ Makes You the ‘Enemy,’ But Marjorie Taylor Greene Doesn't Seem to Care
Trump Says Calling It ‘Artificial Intelligence’ Makes You the ‘Enemy,’ But Marjorie Taylor Greene Doesn't Seem to Care
